Postoperative combined radiotherapy (RT) and chemotherapy (CT) in patients with resected gastric adenocarcinoma
Détails
ID Serval
serval:BIB_7B4F09662C62
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Postoperative combined radiotherapy (RT) and chemotherapy (CT) in patients with resected gastric adenocarcinoma
Titre de la conférence
12th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
Adresse
CHUV Lausanne, April 10-12, 2008
Statut éditorial
Publié
Date de publication
2008
Langue
anglais
Notes
Objective : Postoperative adjuvant CT combined to RT remains the standard of care for high-risk patients with adenocarcinoma of the stomach (AS) or gastroesophageal junction (GEJ), not receiving any neoadjuvant CT. Herein, we assess the outcome of patients treated with the Intergroup (INT-0116) schema.
Materials and Methods : From 2001-2006, 25 patients with high-risk AS or GEJ were treated. Twenty-eight percent of the patients had Portuguese origin. Eighty-eight percent of the patients had pN1-N2, and 28% pT3 tumors. Treatment consisted of postoperative CT/RT (5FU-leucovorin) using 45-Gy 3D
conformal RT or IMRT in all patients.
Results : With a median follow-up of 29 months, 12 patients are alive without disease. The median overall survival (OS) was 41 months. The 3-year OS and disease-free survival (DFS) rates were 61% and 45%, respectively. The 3-year locoregional control rate was 57%. In univariate analyses, the best factors influencing the outcome were good performance status (PS) and
Portuguese origin. Only PS emerged as an independent factor in multivariate analysis. There was no toxic death. Tolerance was acceptable (1 patient with grade 3 leukopenia, and 3 patients with grade 3 gastrointestinal toxicity).
Conclusions : Adjuvant CT/RT is tolerated, and offers a long-term survival with acceptable morbidity in selected patients with AS or GEJ.
Materials and Methods : From 2001-2006, 25 patients with high-risk AS or GEJ were treated. Twenty-eight percent of the patients had Portuguese origin. Eighty-eight percent of the patients had pN1-N2, and 28% pT3 tumors. Treatment consisted of postoperative CT/RT (5FU-leucovorin) using 45-Gy 3D
conformal RT or IMRT in all patients.
Results : With a median follow-up of 29 months, 12 patients are alive without disease. The median overall survival (OS) was 41 months. The 3-year OS and disease-free survival (DFS) rates were 61% and 45%, respectively. The 3-year locoregional control rate was 57%. In univariate analyses, the best factors influencing the outcome were good performance status (PS) and
Portuguese origin. Only PS emerged as an independent factor in multivariate analysis. There was no toxic death. Tolerance was acceptable (1 patient with grade 3 leukopenia, and 3 patients with grade 3 gastrointestinal toxicity).
Conclusions : Adjuvant CT/RT is tolerated, and offers a long-term survival with acceptable morbidity in selected patients with AS or GEJ.
Création de la notice
15/04/2009 9:17
Dernière modification de la notice
20/08/2019 15:37
Données d'usage
